Navigation Links
Promidian Survey Finds Growing Support for Patient-Centered Medical Home
Date:3/29/2011

BERKELEY HEIGHTS, N.J., March 29, 2011 /PRNewswire/ -- Promidian, a management consulting firm focused on the pharmaceutical and biotechnology industries, today announced top-line survey findings about the increasing interest in the patient-centered medical home (PCMH), a patient-centric delivery-of-care model that is rapidly gaining nationwide attention for its potential to improve quality and access to health care—while reducing costs.

The Promidian PCMH survey was completed in March 2011 and included a nationwide mix of 181 stakeholders, including physicians, medical directors, nurses, and administrators and executives from medical group practices, health plans, pharmaceutical companies, and employer groups. The survey found that

  • Patient engagement in care, access to care, and a team approach to care are viewed as the most important components of a PCMH;
  • Priority disease states highlighted by PCMHs include diabetes, cardiovascular disease, asthma, obesity, and stroke;
  • Medication adherence is viewed as extremely important to the success of a PCMH, and PCMHs are considering and evaluating a number of tactics to improve medication adherence;
  • The vast majority of PCMH representatives are interested in receiving targeted resources to help achieve or maintain accreditation (eg, programs, tools, and training).

"Our survey identified a number of key priorities and challenges for PCMHs, as well as highlighted opportunities for pharmaceutical companies to positively influence and support the evolution of this innovative care delivery model," said Kevin Barnett, Executive Vice President and Managing Director for Promidian.

The complete results of the survey will be available at the Promidian exhibit booth at the Patient-Centered Primary Care Collaborative (PCPCC) Conference on March 29-31, at the Ronald Reagan Building, International Trade Center in Washington, DC.

About Promidian

Promidian is a management consulting firm that is focused on the pharmaceutical, biotechnology, and life sciences industries. We combine deep industry and functional area knowledge with specialized expertise in market assessment, analytics, and strategy development—to assist life sciences executives in addressing their most pressing business challenges.

For more information on the PCMH survey or to learn more about Promidian's service offerings, please contact Kevin Barnett, Executive Vice President, at kbarnett@promidianconsulting.com, or visit our Web site at www.promidianconsulting.com.

Promidian is a company of the Access Group (www.theaccessgroup.com).


'/>"/>
SOURCE Promidian
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Survey Emphasizes Value of Biopharmaceutical Company Engagement With Healthcare Providers
2. New Nationwide Survey Identifies Need for Increased Dialogue Between Gastroesophageal Reflux Disease or Frequent Heartburn Sufferers and Health Care Providers
3. National Nasal Allergy Survey Reveals Unmet Needs Still Exist Among Patients Living With Allergic Rhinitis
4. Survey Sampling International Names Chris DeAngelis to Head New SSI Health
5. Reportlinker Adds Global Physician Survey on Stents, Stent-Grafts and Vulnerable Plaque Treatment 2011
6. Thats Nice LLC Launches Nice Insight Marketing Intelligence for CRAMs With Its Pharma & Biotech Outsourcing Survey
7. Survey Finds Patients Oppose Prescription Mandate for OTC Medicines Containing Pseudoephedrine
8. Sixty Percent of Surveyed Type 2 Diabetes Patients in the U.S. Who Use Insulin Indicate They Would Request a Switch to a Less Expensive Biosimilar Insulin if Such an Agent Became Available
9. On Average, 55 Percent of Surveyed U.S. Asthma Patients Say They Are Likely to Request a Switch to a Drug With Efficacy Comparable to Their Current Medication but Which is Dosed Just Once a Day
10. Reportlinker Adds Healthcare Reform: 2010 Medical Device Industry Perceptions Survey
11. A Majority of Surveyed PCPs and Endocrinologists Indicate that they will Prescribe Contrave, Lorqess and Qnexa if these Therapies are Approved for Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host its fiscal ... Friday, November 3, 2017, beginning at 7:00 a.m. (CDT) ... a.m. (CDT) / 9:30 a.m. (EDT). In ... guidance for 2018, Hill-Rom executives will also highlight the ... long-range financial outlook through 2020. ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/22/2017)... -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN ... with the widespread pain associated with fibromyalgia in the ... Essex, England commented, "I had difficulty ... sleep at all, tremendous pain, with every movement sending ... AVACEN 100] enough, how this has and is helping ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s to ... and tested to meet the highest standard. , These products are also: ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
Breaking Medicine News(10 mins):